20 results found.

Hematological Malignancies, Certain Lysosomal Storage and Peroxis Clinical Trial using A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)

Center for International Blood and Marrow Transplant Research - Recruiting N/A or older.
- A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications.
A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)

Acute Leukemia Clinical Trial using FLT PET/CT; MRI

Masonic Cancer Center, University of Minnesota - Recruiting 18 years to 55 years.
- Positron Emission Tomography (PET) Imaging in Patients With High Risk Hematological Malignancies Receiving Total Body Irradiation (TBI) or Total Marrow Irradiation (TMI) as Part of a Hematopoietic Stem Cell Transplant.
FLT PET/CT; MRI

Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, or Myelodys Clinical Trial using Allopurinol; Keppra; Busulfan; Cyclophosphamide; Cyclosporine A; Mycophenolate mofetil; Allogeneic hematopoietic stem cell transplant; Filgrastim; antithymocyte globulin

Masonic Cancer Center, University of Minnesota - Recruiting N/A to 44 years.
- Busulfan and Cyclophosphamide Followed By Allogeneic Hematopoietic Cell Transplantation In Patients With Hematological Malignancies.
Allopurinol; Keppra; Busulfan; Cyclophosphamide; Cyclosporine A; Mycophenolate mofetil; Allogeneic hematopoietic stem cell transplant; Filgrastim; antithymocyte globulin

Hematological Malignancies Clinical Trial using KPT-330

NPM Pharma Inc. - Recruiting 18 years or older.
- A Phase I Study of the Safety, Pharmacokinetics and Pharmacodynamics of Escalating Doses of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced Hematological Malignancies.
KPT-330

Non-Hodgkin's Lymphoma (NHL), Multiple Myeloma, Waldenstrom's Mac Clinical Trial using CB-839

Calithera Biosciences, Inc - Recruiting 18 years or older.
- A Phase 1 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Glutaminase Inhibitor CB-839 in Patients With Advanced and/or Treatment-Refractory Hematological Malignancies.
CB-839

Lung or Prostatic Neoplasms, Colorectal or Kidney Neoplasms, Panc Clinical Trial using NK cells +CliniMACs CD3 and CD56 systems

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 70 years.
- Safety and the Anti-Tumor Effects of Escalating Doses of Adoptively Infused Ex Vivo Expanded Autologous Natural Killer (NK) Cells Against Metastatic Cancers or Hematological Malignancies Sensitized to NK TRAIL Cytotoxicity With Bortezomib.
NK cells +CliniMACs CD3 and CD56 systems

Cancer Clinical Trial using SNX-5422

Esanex Inc. - Recruiting 18 years or older.
- A Phase 1, Open-label, Dose-escalation Study of the Safety of SNX-5422 Mesylate in Subjects With Refractory Hematological Malignancies.
SNX-5422

Acute Myelogenous Leukemia (AML) in 1st or Subsequent Remission, Clinical Trial using POL6326; Leukapheresis; PBSC Transplant

Polyphor Ltd. - Recruiting 18 years to 75 years.
- A Phase I/II Study Evaluating the Safety and Efficacy of Intravenous POL6326 for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Patients With Advanced Hematological Malignancies.
POL6326; Leukapheresis; PBSC Transplant

Leukemia, Myelodysplastic Syndrome, or Lymphoma Clinical Trial using CliniMACS Fractionation system (Arm A); CliniMACS Fractionation system (Arm B)

Memorial Sloan-Kettering Cancer Center - Recruiting 2 years to 70 years.
- Myeloablative Unrelated Donor Cord Blood Transplantation With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cells for Patients With High Risk Hematological Malignancies.
CliniMACS Fractionation system (Arm A); CliniMACS Fractionation system (Arm B)

Acute Lymphocytic Leukemia, or Adult Lymphoblastic Lymphoma Clinical Trial using DNR; VCR; PEG-asp; CTX; Prednisone; Liposomal AraC; MTX; LCV; AraC; Etoposide; Dasatinib; Rituximab; Hydrocortisone

University of California, San Diego - Recruiting 18 years to 60 years.
- A Phase II Study of Punctual, Cyclic, and Intensive Chemotherapy With Liposomal Cytarabine (Depocytr) CNS Prophylaxis for Adults With Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma.
DNR; VCR; PEG-asp; CTX; Prednisone; Liposomal AraC; MTX; LCV; AraC; Etoposide; Dasatinib; Rituximab; Hydrocortisone

Hematological Malignancy Clinical Trial using SAR650984

Sanofi - Recruiting 18 years or older.
- A Phase I Dose Escalation Safety and Pharmacokinetic Study of Multiple Intravenous Administrations of a Humanized Monoclonal Antibody (SAR650984) Against CD38 In Patients With Selected CD38+ Hematological Malignancies.
SAR650984

MDS (Myelodysplastic Syndrome), Myeloproliferative Disorder, Lymp Clinical Trial using Graft Manipulation (CD34+ Selection)

National Institutes of Health Clinical Center (CC) - Recruiting 2 years to 80 years.
- Peripheral Blood Stem Cell Allotransplantation For Hematological Malignancies Using Ex Vivo CD34 Selection - a Platform For Adoptive Cellular Therapies.
Graft Manipulation (CD34+ Selection)

Myeloid Hematological Malignancies Clinical Trial using Busulfan; Cyclophosphamide; Fludarabine; Cord Blood Stem Cell Infusion

Baylor College of Medicine - Recruiting N/A or older.
- Umbilical Cord Blood Transplant for Children With Myeloid Hematological Malignancies (UCAML).
Busulfan; Cyclophosphamide; Fludarabine; Cord Blood Stem Cell Infusion

Hematological Malignancies Clinical Trial using KRP203

Novartis - Recruiting 18 years to 65 years.
- A Single-arm, Open-label Study to Evaluate the Safety, Tolerability and Pharmacokinetics of KRP203 in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant for Hematological Malignancies.
KRP203

For Donors:, Related Donors Donating PBSC to a Family Member, For Clinical Trial using Plerixafor

Center for International Blood and Marrow Transplant Research - Recruiting 18 years to 65 years.
- A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Recipients With Hematological Malignancies.
Plerixafor

Neoplasms, or Hematologic Neoplasms Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 2 years or older.
- Collection of Blood, Bone Marrow, Urine, and/or Tissue Samples From Patients With Solid Tumors, Hematological Malignancies or Non-Malignant Hematologic Disorders or HLA Compatible Family Members.

Hematological Malignancies Clinical Trial using Total Body Irradiation; Cyclophosphamide; Tacrolimus; Mycophenolate mofetil; Fludarabine; Thiotepa; Hematopoietic stem cell transplantation

Thomas Jefferson University - Recruiting 18 years or older.
- Post Transplant Cyclophosphamide for Unrelated and Related Allogeneic Hematopoietic Stem Cell Transplantation for Hematological Malignancies.
Total Body Irradiation; Cyclophosphamide; Tacrolimus; Mycophenolate mofetil; Fludarabine; Thiotepa; Hematopoietic stem cell transplantation

Acute Myelocytic Leukemia, Acute Lymphocytic Leukemia, Chronic My Clinical Trial using HSC835

Novartis - Recruiting 10 years to 55 years.
- A First-in-human, Single-arm, Single-center, Open-label, Proof-of-concept Study to Evaluate the Safety and Tolerability of Infusing HSC835 (LFU835-expanded Umbilical Cord Blood Hematopoietic Stem Cells) in Patients With Hematological Malignancies.
HSC835

Hematological Malignancies, Acute Lymphoblastic Leukemia (ALL), A Clinical Trial using NiCordr

Gamida Cell ltd - Recruiting 18 years to 65 years.
- Allogeneic Stem Cell Transplantation of NiCordr, Umbilical Cord Blood-derived Ex Vivo Expanded Stem and Progenitor Cells, in Adult Patients With Hematological Malignancies.
NiCordr

Hematological Malignancies, or Allogeneic Transplantation Clinical Trial using treosulfan

Hospices Civils de Lyon - Recruiting 18 years to 65 years.
- Unrelated Reduced Intensity Conditioning With Treosulfanr for Allogeneic Stem Cell Transplantation in Patients With Hematological Malignancies.
treosulfan